Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Boltwood Capital Management

Boltwood Capital Management cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 15.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,758 shares of the medical equipment provider’s stock after selling 685 shares during the quarter. Boltwood Capital Management’s holdings in Zimmer Biomet were worth $397,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Dunhill Financial LLC increased its position in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $28,000. Bangor Savings Bank purchased a new stake in shares of Zimmer Biomet during the 3rd quarter valued at approximately $31,000. Brooklyn Investment Group acquired a new position in Zimmer Biomet in the third quarter valued at approximately $35,000. Finally, Quarry LP purchased a new position in Zimmer Biomet in the second quarter worth approximately $53,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ZBH shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Truist Financial lifted their price target on shares of Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Barclays decreased their price objective on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a report on Thursday, December 12th. Wolfe Research began coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating for the company. Finally, Canaccord Genuity Group decreased their price target on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $123.33.

Zimmer Biomet Stock Down 0.2 %

ZBH stock traded down $0.23 during midday trading on Monday, reaching $104.24. 205,164 shares of the company were exchanged, compared to its average volume of 753,810. The company has a market cap of $20.75 billion, a price-to-earnings ratio of 19.82, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The stock’s 50-day simple moving average is $108.37 and its 200 day simple moving average is $108.20.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.65 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s payout ratio is 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.